Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Folds In Schering-Plough, Begins Job Cuts

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck will cut 15,000 jobs in the first phase of a restructuring program intended to integrate Schering-Plough and save $2.6 billion to $3 billion by 2012.

You may also be interested in...



Pfizer Lowers Targeted Revenues For 2012; Wall Street Remains Skeptical

With the Wyeth integration well under way, Pfizer did what analysts claimed it was going to do for months - it lowered its 2012 revenue targets to $66 billion-$68.5 billion from $70 billion, the figure it initially projected when it announced the Wyeth merger a year ago. But these figures still tower above Wall Street's expectations

Merck’s Heart Failure Drug Flunks Phase III

Rolofylline fails to meet primary and secondary endpoints in a Phase III trial.

Merck/Schering: The Next Wave Of Consolidation

$41.1 bil. acquisition will create a cardiovascular powerhouse, buffer Merck against patent expirations of Singulair, Cozaar/Hyzaar and generate $3.5 bil in savings.

Topics

UsernamePublicRestriction

Register

PS070232

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel